SCM
ELEV

Stonepine Capital Management’s Elevation Oncology ELEV Stock Holding History

Stonepine Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$113K – 70
2024
Q4 		$113K Buy
+200,000
New +$118K 0.09% 47

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stonepine Capital Management's ELEV Position: Q1 2025 in Review

Stonepine Capital Management sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 200,000 shares — an estimated $113K sold.

Stonepine Capital Management first reported a position in ELEV in Q4 2024 and held it in 1 quarter. The position peaked at $113K in Q4 2024. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

  • Stonepine Capital Management reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 200,000 Elevation Oncology shares in Q1 2025, an estimated $113K.
  • Stonepine Capital Management first reported a position in Elevation Oncology in Q4 2024 and held it in 1 quarter.
  • Stonepine Capital Management's Elevation Oncology position peaked at $113K in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.